Recently, Canadian judges have invalidated the patents for 18 medicines belonging to multiple companies based upon a unique “Promise of the Patent” doctrine. These rulings have created a high level of unpredictability with the Canadian market and damaged innovation. Today’s LinkPad takes a look at the current situation:
- Forbes discusses the importance of strong IP protection to create incentives for innovation. The U.S. government must address unfair policies in countries like Canada and India, as they undermine innovation and threaten American competitiveness.
- The Hill’s blog explains how the growing trend in Canada to revoke pharmaceutical patents impacts future innovation.
- Howard Schneider’s article in the Washington Post describes the balance needed between access to medicines and the actual development of medicines. Canada and India give priority to the first, which in turn affects the second.
- Inside Trade (subscription required) talks about how future drug patent invalidations could have implications for the Trans-Pacific Partnership (TPP).
Canada’s actions could have global implications. The future of biopharmaceutical innovation relies on IP protection, and Canada should take the lead and implement policies that better protect new medicines. For a Canadian perspective, check out LillyPad Canada.